JiveSync

Johnson & Johnson has no plans to start making weight-loss drugs because there’s already too much competition, according to Chief Executive Officer Joaquin Duato.

The company has enough on its plate, Duato said Tuesday at the firm’s investor day. J&J is instead focused on broadly expanding in areas such as neurology and oncology.

ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGilnq%2BjZK6zwMico56rX2d9c3%2BMamlmaGVkt262jJycqGWjlsa0edaeoKCgpGK5sL%2FSZpurrZdiuqK%2Byp6rZqGjYsGwu4ycqaivlJqxbsDOZpynrJWn